Physician profile
Charles Shaw
NPI 1417100223
$1,123.19
in general payments reported to CMS, 2019-2025
16 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2021: $23.86 · 2022: $19.70 · 2024: $20.79 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $182.25 | 2019-2024 | Wegovy |
| Astellas Pharma US INC | $121.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.91 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $113.98 | 2019 | |
| Exact Sciences Corporation | $113.59 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $90.90 | 2019 | |
| Amarin Pharma, INC. | $70.30 | 2019 | |
| Lilly USA, LLC | $68.41 | 2019 | |
| Arbor Pharmaceuticals, INC. | $53.27 | 2019 | |
| Amgen INC. | $50.47 | 2019 | |
| Merck Sharp & Dohme LLC | $42.77 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $27.84 | 2019 | |
| Pfizer INC. | $24.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.74 | 2019 | |
| Glaxosmithkline, LLC. | $13.89 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $13.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.